Phase Ib study of Orca-T in patients with advanced hematologic malignancies

Download video

Phase Ib study of Orca-T in patients with advanced hematologic malignancies

766 views

VJHemOnc – Video Journal of Hematology & HemOnc

2 years ago

Phase Ib study of Orca-T in patients with advanced hematologic malignancies

4:26

Phase Ib study of Orca-T in patients with advanced hematologic malignancies

by VJHemOnc – Video Journal of Hematology \& HemOnc

2:35

Dr. Pardee Discusses a Phase I Study of CPI-613 in Advanced Hematologic Malignancies

by OncLive

21:53

2022 West Oncology Conference | Hematological Malignancies | High-Grade Myeloid Malignancies

by Total Health | Oncology

3:11

A Phase Ib study of add-on therapy with CK0804 in myelofibrosis with suboptimal ruxolitinib response

by VJHemOnc – Video Journal of Hematology \& HemOnc

0:41

LOXO-338 for the treatment of advanced hematological malignancies

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Results of Phase I study of MCL-1 inhibition with AZD5991 in R\/R hematologic malignancies$

1:52

Results of Phase I study of MCL-1 inhibition with AZD5991 in R\/R hematologic malignancies

by VJHemOnc – Video Journal of Hematology \& HemOnc

2:30

TTI-621 for hematologic malignancies: a Phase I dose escalation and expansion study

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Results of a Phase Ib study of ibrutinib + obinutuzumab in R\/R CLL$

2:58

Results of a Phase Ib study of ibrutinib + obinutuzumab in R\/R CLL

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Phase Ib\/II Study of Multi-Targeted Therapy (ViPOR) for #DLBCL | Mark Roschewski, MD | ASH 2023$

2:10

Phase Ib\/II Study of Multi-Targeted Therapy (ViPOR) for #DLBCL | Mark Roschewski, MD | ASH 2023

by HealthTree Foundation for Blood Cancers

47:24

IAPNEOCON 2024 POCUS workshop: Basic PPHN indices in ECHO

by IAP Neonatology Chapter

10:53

Chapter 1: How to do coronary atherectomy? (concepts about coronary calcium) intermediate level

by High risk PCI

$Updated safety \& efficacy data from MANIFEST-2: pelabresib plus ruxolitinib for myelofibrosis$

4:35

Updated safety \& efficacy data from MANIFEST-2: pelabresib plus ruxolitinib for myelofibrosis

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Phase Ib\/IIa study of AZD4573 + acalabrutinib in R\/R DLBCL$

3:58

Phase Ib\/IIa study of AZD4573 + acalabrutinib in R\/R DLBCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

0:57

Dr. Bayard Powell Discusses CPI-613 in Advanced Hematologic Malignancies

by OncLive

52:25

Providing the palliative approach to care for patients with hematological malignancies

by The Leukemia \& Lymphoma Society of Canada

1:42

Dr. Romee on advanced hematologic malignancies | Dana-Farber Cancer Institute

by Dana-Farber Cancer Institute

2:28:58

Session 3: February 7, 2024 – Hematologic Malignancies

by University of Illinois Cancer Center

$Phase IB\/II Study of Nivolumab with Azacytidine in Patients with Relapsed AML$

4:52

Phase IB\/II Study of Nivolumab with Azacytidine in Patients with Relapsed AML

by Oncology.TV

$First-in-Human study of TTI-621 in R\/R hematologic malignancies$

2:24

First-in-Human study of TTI-621 in R\/R hematologic malignancies

by VJHemOnc – Video Journal of Hematology \& HemOnc

4:48

The safety of fedratinib as a maintenance strategy after alloSCT for MPNs: Phase I results

by VJHemOnc – Video Journal of Hematology \& HemOnc

3:18

A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies

by VJHemOnc – Video Journal of Hematology \& HemOnc

30:00

Expert Perspectives: Hematologic Malignancies

by HMP Education

1:25

Dr. Pardee on CPI-613 in Hematologic Malignancies

by OncLive

Best on Vidoe

Phase Ib study of Orca-T in patients with advanced hematologic malignancies